Bayforest Capital Ltd bought a new stake in shares of Bath & Body Works, Inc. (NYSE:BBWI - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 14,140 shares of the company's stock, valued at approximately $429,000.
Several other large investors also recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Bath & Body Works by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company's stock valued at $17,063,000 after buying an additional 36,684 shares during the period. Great Lakes Advisors LLC grew its position in Bath & Body Works by 1,387.2% during the first quarter. Great Lakes Advisors LLC now owns 79,447 shares of the company's stock valued at $2,409,000 after buying an additional 74,105 shares during the period. Sciencast Management LP grew its position in Bath & Body Works by 48.9% during the first quarter. Sciencast Management LP now owns 116,219 shares of the company's stock valued at $3,524,000 after buying an additional 38,183 shares during the period. Goldman Sachs Group Inc. grew its position in Bath & Body Works by 15.7% during the first quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company's stock valued at $19,586,000 after buying an additional 87,529 shares during the period. Finally, Dynamic Technology Lab Private Ltd grew its position in Bath & Body Works by 50.5% during the first quarter. Dynamic Technology Lab Private Ltd now owns 102,040 shares of the company's stock valued at $3,094,000 after buying an additional 34,231 shares during the period. 95.14% of the stock is currently owned by institutional investors.
Bath & Body Works Stock Performance
Bath & Body Works stock traded down $0.41 during midday trading on Monday, hitting $26.81. 2,798,172 shares of the company's stock were exchanged, compared to its average volume of 5,297,657. Bath & Body Works, Inc. has a 12 month low of $24.94 and a 12 month high of $41.87. The firm has a 50-day moving average of $30.31 and a two-hundred day moving average of $30.05. The company has a market cap of $5.53 billion, a PE ratio of 7.94, a P/E/G ratio of 0.93 and a beta of 1.49.
Bath & Body Works (NYSE:BBWI - Get Free Report) last released its quarterly earnings results on Thursday, August 28th. The company reported $0.37 EPS for the quarter, meeting the consensus estimate of $0.37. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.55 billion. Bath & Body Works had a net margin of 9.88% and a negative return on equity of 48.43%. The company's quarterly revenue was down .8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.37 earnings per share. Bath & Body Works has set its Q3 2025 guidance at 0.370-0.45 EPS. FY 2025 guidance at 3.350-3.600 EPS. As a group, equities analysts expect that Bath & Body Works, Inc. will post 3.3 earnings per share for the current year.
Bath & Body Works Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, September 5th. Shareholders of record on Friday, August 22nd were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $0.80 dividend on an annualized basis and a yield of 3.0%. Bath & Body Works's dividend payout ratio (DPR) is currently 23.74%.
Analysts Set New Price Targets
Several brokerages have weighed in on BBWI. Wall Street Zen downgraded shares of Bath & Body Works from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Citigroup lowered their price target on shares of Bath & Body Works from $42.00 to $40.00 and set a "buy" rating on the stock in a report on Tuesday, August 19th. Morgan Stanley lowered their price target on shares of Bath & Body Works from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Friday. Telsey Advisory Group reaffirmed an "outperform" rating and set a $38.00 price target on shares of Bath & Body Works in a report on Thursday, August 28th. Finally, UBS Group lowered their price target on shares of Bath & Body Works from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, August 29th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $39.69.
Get Our Latest Research Report on Bath & Body Works
Bath & Body Works Profile
(
Free Report)
Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
Featured Stories

Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.